Defense World
04 Apr 2026, 08:57 UTC · 31w ago
Verdict
Headline takes no side. We score AXGN +0.20 across four claims — slightly bullish.
+0.20slightly bullish
More positive than 53% of ticker scores this week
Scored by the NIS engine · methodology.
What the story claims
4 claims · scored −1 bearish … +1 bullish
AxoGen reported Q4 earnings per share of $0.07, missing the consensus estimate of $0.08.
More negative than 90% of claims this week
Citizens Jmp raised its price target on AxoGen from $34.00 to $42.00 while maintaining a 'market outperform' rating.
Continue reading
5 related stories
Top 1 mover · tap to explore
More positive than 76% of claims this week
JPMorgan Chase & Co. reduced its holdings in AxoGen by 44.9%, selling 170,067 shares in the third quarter.
More negative than 78% of claims this week
Insider Erick Wayne Devinney sold 5,221 shares of AxoGen stock on March 16th, reducing their position by 1.95%.
More negative than 70% of claims this week
Which stocks this story touches
More positive than 53% of ticker scores this week
Mixed signals with a missed earnings report and a large JPMorgan sale, but offset by multiple analyst upgrades, price target increases, and increased holdings from several other institutional investors.
More positive than 47% of ticker scores this week
Mentioned as part of a portfolio holding with an additional purchase by JPMorgan Chase.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
24/7 Wall Street
23h ago
+45.2%
Price agrees with the score
$50.02 vs $34.44 close before publication (Apr 2) · not market-adjusted
AXGN chart →
